Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma

World Journal of Surgical Oncology

Research

Xiang-Peng Meng¹  Xu-Yong Teng¹  Zhen Liu¹  Bao-Sheng Wang¹ 

[1] Department of General Surgery, Shengjing Hospital, China Medical University, No. 36 Sanhao Street, 110004, Shenyang, China;

关键词: chemokine;    chemokine receptors;    CXCR7;    pancreatic neoplasms;    SDF-1;   

DOI  :  10.1186/1477-7819-12-348

 received in 2014-02-01, accepted in 2014-10-03,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundStromal cell-derived factor 1 (SDF-1) is a chemokine that is expressed in some cancer cells and is involved in tumor cell migration and metastasis. CXCR7, a novel receptor for SDF-1, has been identified recently. Research has demonstrated that SDF-1/CXCR7 interaction could play an important role in cancer progression. In this study, we aimed to investigate the expression of the SDF-1/CXCR7 ligand receptor system and the relationship between this expressions and clinicopathological characteristics in pancreatic adenocarcinoma.MethodsExpressions of SDF-1 and CXCR7 in 64 cases of pancreatic adenocarcinoma tissue and 24 cases of normal pancreatic tissue were detected immunohistochemically.ResultsExpressions of SDF-1 and CXCR7 were negative in normal pancreatic tissues. Respectively, positive expression rates of SDF-1 and CXCR7 in pancreatic adenocarcinoma were 45.3% and 51.6%. The expression of SDF-1 correlated with histological grades; the expression rate in moderate to low differentiation was higher than in high differentiation (P <0.05). The expression of CXCR7 positively correlated with lymph node metastasis (P <0.05). A log-rank test showed that the expression of SDF-1+/CXCR7+ correlated with poor prognosis (P <0.05).ConclusionsThe SDF-1/CXCR7 receptor ligand system may take part in invasive progression and metastasis of pancreatic adenocarcinoma, and might be useful as an index for evaluating invasiveness and prognosis.

【 授权许可】

CC BY   
© Liu et al.; licensee BioMed Central Ltd. 2014